Health Canada approves UPLIZNA® (inebilizumab injection) for the treatment of neuromyelitis optica spectrum disorder (NMOSD)
Horizon Therapeutics plc, now a component of Amgen, announced that on December 15, 2023, Health Canada approved UPLIZNA® (inebilizumab injection) as monotherapy for the treatment of adult patients with NMOSD who are AQP4-IgG. This rare autoimmune disease is caused by inflammation of the central nervous system, which causes severe and recurrent seizures that can lead to permanent disability, such as vision loss and paralysis. 1 An estimated 1,000 other people in Canada are living with the disease. 2,3,4